NCT01557166

Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea

Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea. A 32 Week Randomised, Double-blind, Placebo-controlled, Parallel Group, Multi-centre and Multinational Trial

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 359 (actual)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: 18 Years – 64 Years
• Healthy volunteers: Not accepted

Summary

This trial is conducted in North America. The aim of the trial is to investigate the effect of liraglutide in obese subjects with sleep apnoea.

Conditions

• Metabolism and Nutrition Disorder
• Obesity
• Obstructive Sleep Apnoea

Interventions

Type	Name	Description
DRUG	liraglutide	3.0 mg liraglutide administered subcutaneously (s.c., under the skin) once daily for 32 weeks + diet and exercise
DRUG	placebo	Placebo administered subcutaneously (s.c., under the skin) once daily for 32 weeks + diet and exercise

Timeline

• Start date: 2012-06-07
• Primary completion: 2013-06-01
• Completion: 2013-06-17
• First posted: 2012-03-19
• Last updated: 2017-11-01
• Results posted: 2015-02-09

Locations

42 sites across 2 countries: United States, Canada